Inari Medical

General Information


We are a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Our initial product offering consists of two minimally-invasive, novel catheter-based mechanical thrombectomy devices. We purpose-built our products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE – deep vein thrombosis and pulmonary embolism. Our ClotTriever product is FDA-cleared for the removal of clot from peripheral blood vessels and is used to treat patients suffering from deep vein thrombosis, or DVT. Our FlowTriever product is the first thrombectomy system FDA-cleared for the treatment of pulmonary embolism, or PE.

Employees: 240
Founded: 2011
Contact Information
Address 9 Parker, Suite 100, Irvine, CA 92618, US
Phone Number (877) 923-4747
Web Address
View Prospectus: Inari Medical
Financial Information
Market Cap $806.4mil
Revenues $71.1 mil (last 12 months)
Net Income $3.9 mil (last 12 months)
IPO Profile
Symbol NARI
Exchange NASDAQ
Shares (millions): 8.2
Price range $19.00 - $19.00
Est. $ Volume $155.8 mil
Manager / Joint Managers BofA Securities/Morgan Stanley
CO-Managers Canaccord Genuity/ Wells Fargo Securities
Expected To Trade: 5/22/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change